Enliven Therapeutics, Inc.
ELVN Nasdaq
SEC CIK 1672619
Follow Enliven Therapeutics
Weekly email: filings, results
Net income
−$27.7M
−37.5% vs same quarter last year
EPS, diluted
−$0.36
−12.5% vs same quarter last year
Operating cash flow
−$12.6M
+5.5% vs same quarter last year
Operating income
−$36M
−43.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$103.7M |
| FY24 | −$89M |
| FY23 | −$71.6M |
| FY22 | −$37.7M |
| FY21 | −$24.7M |
| FY20 | −$41.4M |
| FY19 | −$23.5M |
| FY18 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$70.5M |
| FY24 | −$73.2M |
| FY23 | −$61.4M |
| FY22 | −$32.7M |
| FY21 | −$19.3M |
| FY20 | −$37.4M |
| FY19 | −$22M |
| FY18 | - |